|

Ezabenlimab Clinical Trials

3 actively recruiting trials across 2 locations

No change since May 2026

Also known as: BI 754091

Pipeline

Phase 1: 3

Top Sponsors

  • Boehringer Ingelheim2
  • Johann Wolfgang Goethe University Hospital1

Indications

  • Cancer3
  • Solid Tumors2
  • Glioblastoma1

Other1 trial

Intracranial Injection of NK-92/5.28.z Cells in Combination With Intravenous Ezabenlimab in Patients With Recurrent HER2-positive Glioblastoma
Phase 1

Los Angeles, California1 trial

A Study to Test How Different Doses of BI 1703880 in Combination With Ezabenlimab Are Tolerated in People With Different Types of Advanced Cancer (Solid Tumours)

Valkyrie Clinical Trials

Phase 1

Indianapolis, Indiana1 trial

A Study to Test Different Doses of BI 3923948 Alone and in Combination With an Anti-PD-1 Antibody in People With Different Types of Advanced Cancer (Solid Tumors)

Indiana University

Phase 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.